Pharmacological Voluntary Termination of Pregnancy: Predictors of Pelvic Pain During Treatment (NCT06800287) | Clinical Trial Compass
CompletedNot Applicable
Pharmacological Voluntary Termination of Pregnancy: Predictors of Pelvic Pain During Treatment
Italy13 participantsStarted 2021-07-13
Plain-language summary
Pharmacological treatment for voluntary termination of pregnancy is a safe and effective practice, but has as its limitation a greater need for analgesic coverage than surgical treatment. Despite this, to date there are no specific guidelines on the management of pain therapy during pharmacological voluntary termination of pregnancy and in particular on its correlation with gestational age at the time of treatment. The aim of the study is to investigate the correlation between the pain symptoms reported by the patients and the gestational age at the time of the pharmacological voluntary interruption of pregnancy and to identify the presence of possible predictive factors, in order to be able to outline the correct therapeutic management.
Who can participate
Age range
18 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients over 18 years of age
* IVG certificate issued by the doctor and signed by the woman
* Informed consent for drug treatment
* Informed consent for the study in question
* Pregnancy in utero with ultrasound date less than or equal to 63 days
Exclusion Criteria:
* Suspected extrauterine pregnancy or adnexal masses of undefined diagnosis
* IUD in place
* Severe anaemia
* Hereditary porphyria
* Coagulopathy or ongoing treatment with anticoagulants
* Ongoing treatment with corticosteroids or adrenal insufficiency
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Pain symptoms of patients undergoing pharmacological IVG
Timeframe: 48 hours after the administration of mifepristone and after an observation period of not less than 3 hours
Trial details
NCT IDNCT06800287
SponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna